Dramatic Q4 Unveiling: Swiggy’s Growth Gambit Faces the Profitability Test!

It's a blockbuster Friday on Dalal Street as Swiggy, Dr Reddy's Laboratories, Manappuram Finance, and a slew of other market movers prepare to release their Q4 FY25 numbers. Here's what's making news as the numbers come in:

 

Key Highlights

 

Swiggy's Growth Story Continues

Swiggy will report strong Q4 revenue growth, with estimates ranging from a 26–35% year-on-year rise, led by exploding order volumes in food delivery and its instant commerce business, Instamart. Revenue will reach ₹4,227–4,285 crore. Losses are, however, expected to expand, possibly to ₹1,031 crore, as the company continues to invest aggressively in customer acquisition and promotional expenses. Investors are keeping a close eye on Instamart's performance and its margins when expansion becomes aggressive. Swiggy's results will be announced after 4 PM and there is no investor call planned for this occasion.

 

Dr Reddy's Laboratories Sees Double-Digit Profit Rise:

The pharma behemoth is seen to report a good quarter, with net profit likely to grow 12–18.6% year-on-year at ₹1,439–1,456 crore. Topline is estimated between ₹7,981–8,424 crore, up to 18% driven by the Nicotinell acquisition and US market growth. Commentary from management on US generics, margin trajectory, and integration of new businesses is awaited by analysts.

 

Manappuram Finance and Others in Focus:

Manappuram Finance, and other big guns such as Union Bank, Titan, and CE Info Systems, will also post earnings today, so it is going to be a high-tension day for market observers. Union Bank's post-market-hour announcement yesterday already gave the lead with a 51% YoY profit increase.

 

Watch this space as the earnings procession marches on, promising surprises, daring strategies, and market-defining action!

 

Sources: CNBC-TV18, Business Standard, Economic Times, Goodreturns, Value Research Online